Prep for New Prenatal Dx

Premium

In March, Sequenom disclosed that it had initiated discussions with the US Food and Drug Administration to try to obtain premarket approval for its sequencing-based prenatal diagnostic test for trisomy 21, SensiGene T21. During a conference call with investors and reporters to discuss its fourth-quarter earnings for 2010, Sequenom also said it expects to offer SensiGene T21 as a lab-developed test to physicians in late 2011, or by early 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.